News

   

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

Los Angeles, California, USA, November 22nd, 2022 – ImaginAb…

Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage

Dan Mahony and Gareth Powell are long time, successful life sciences…

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V.…

ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

Los Angeles, California, USA, November 15, 2022 – ImaginAb…

Destiny Pharma plc – XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID

Brighton, United Kingdom, 15th November 2022 - Destiny Pharma…

Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 15…

Leading Pharma & Biotech Journalist Richard Staines Joins Optimum

14 November 2022 - Optimum Strategic Communications ("Optimum"),…

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight

Financing growth: Walking the tightrope InsightIn the context…

Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program

Agreement enables use of CD8 ImmunoPETTM Imaging Technology…

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

Industry expert Ulrik Mouritzen M.D. appointed Chief Executive…

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

 The companies enter into a license agreement for the European…

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Access to up to $400 million expected to provide cash runway…

Sequana Medical to present at Jefferies London Healthcare Conference

Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext…

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

First-in-human study investigating the safety and immunogenicity…

Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference

We were proud to host a fantastic panel chaired by BioCentury’s…

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

Inobrodib is a pioneering drug targeting twin tumour drivers…

Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK

Consensus group of clinicians have developed a framework…

Novo Holdings acquires KabaFusion from Pritzker Private Capital. KabaFusion’s clinician-led management team will remain significant investors in the business alongside Novo Holdings

Novo Holdings, a leading healthcare investment firm, announced…

Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia

The grant will enable leading international researchers to complete…

AMSilk Invited to Participate in VISION 2045 Summit

Leaders from across the world will convene at VISION 2045 Summit…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

Get in touch
© Optimum Strategic Communications.